Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness
NCT ID: NCT02029989
Last Updated: 2024-04-04
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
121 participants
INTERVENTIONAL
2010-02-28
2012-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Monitoring and Management for Metabolic Side Effects of Antipsychotics
NCT01875861
Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness
NCT02167620
Determining Metabolic Effects of Valproate and Antipsychotic Therapy
NCT00167934
Lifestyle Intervention for Diabetes and Weight Management in Psychosis
NCT01828931
Diabetes Prevention Program in Schizophrenia [DPPS]
NCT00182494
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Extended Treatment Group
Glucose and Lipids and Glycosylated Hemoglobin A1c and Blood Pressure and Heart Rate and Body Mass Index and Waist and Hip Circumference and Comprehensive Medication Management
Glucose and lipids
Point-of-care (POCT) screening for diabetes and dyslipidemia.
Glucose and Lipids
Glycosylated Hemoglobin A1c
Point-of-care (POCT) screening for diabetes
Glycosylated Hemoglobin A1c
Blood Pressure and Heart Rate
Point-of-care (POCT) screening for hypertension
Blood Pressure and Heart Rate
Body mass index
Height and weight measurement used to calculate BMI = Mass(kg)/(height (m))squared
Waist and Hip circumference
Measurement for Central Obesity
Waist and Hip circumference
Comprehensive Medication Management
Defined at http://www.pcpcc.org/guide/patient-health-through-medication-management
Usual Treatment Group
Glucose and Lipids and Glycosylated Hemoglobin A1c and Blood Pressure and Heart Rate and Body Mass Index and Waist and Hip Circumference
Glucose and lipids
Point-of-care (POCT) screening for diabetes and dyslipidemia.
Glucose and Lipids
Glycosylated Hemoglobin A1c
Point-of-care (POCT) screening for diabetes
Glycosylated Hemoglobin A1c
Blood Pressure and Heart Rate
Point-of-care (POCT) screening for hypertension
Blood Pressure and Heart Rate
Body mass index
Height and weight measurement used to calculate BMI = Mass(kg)/(height (m))squared
Waist and Hip circumference
Measurement for Central Obesity
Waist and Hip circumference
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Glucose and lipids
Point-of-care (POCT) screening for diabetes and dyslipidemia.
Glucose and Lipids
Glycosylated Hemoglobin A1c
Point-of-care (POCT) screening for diabetes
Glycosylated Hemoglobin A1c
Blood Pressure and Heart Rate
Point-of-care (POCT) screening for hypertension
Blood Pressure and Heart Rate
Body mass index
Height and weight measurement used to calculate BMI = Mass(kg)/(height (m))squared
Waist and Hip circumference
Measurement for Central Obesity
Waist and Hip circumference
Comprehensive Medication Management
Defined at http://www.pcpcc.org/guide/patient-health-through-medication-management
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-64
* Competent to understand and make medical choices independently
Exclusion Criteria
18 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medica Foundation
OTHER
University of Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Human Development Center
Duluth, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Schneiderhan ME, Shuster SM, Davey CS. Twelve-month prospective randomized study of pharmacists utilizing point-of-care testing for metabolic syndrome and related conditions in subjects prescribed antipsychotics. Prim Care Companion CNS Disord. 2014 Oct 30;16(5):10.4088/PCC.14m01669. doi: 10.4088/PCC.14m01669. eCollection 2014.
Schneiderhan ME, Li X. Observed Sex Differences in Cardiometabolic Indices in Patients on Antipsychotics: Secondary Analyses of a 12-Month Multicenter, Randomized, Controlled Trial. Prim Care Companion CNS Disord. 2021 Apr 8;23(2):19m02493. doi: 10.4088/PCC.19m02493.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
090M72212
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.